European launch of HERAFILL beads G – Bone Graft ... - Orthoworld

European launch ofHERAFILL ® beads G –Bone Graft Substitute with Gentamicinfrom Heraeus MedicalHeraeus Medical’s new synthetic bone graft substitutewith gentamicin can be used in the osseous skeleton for anumber of indications requiring the filling of bone voids, whichare either infected or at risk of infection. For example,Osteomyelitis or infected non-unions are just two suchindications.HERAFILL ® beads G is a unique composition of calciumsulphate, calcium carbonate, tripalmitate and the recognizedantibiotic gentamicin sulphate, which has a bactericidal effectagainst gram-negative pathogens. The high initial release ofgentamicin from HERAFILL ® beads G during the first 72 hoursachieves concentrations that are higher than the MIC (minimuminhibitory concentration) of many pathogens relevant to boneinfection. HERAFILL ® beads G reduces the risk of infection inthe wound and promotes bone regeneration.- 1 -

Heraeus, the precious metals and technology groupheadquartered in Hanau, Germany, is a global, private companywith over 155 years of tradition. Our businesses include preciousmetals, sensors, dental products and biomaterials, as well asquartz glass and specialty lighting sources. With product revenuesapproaching € 3 billion and precious metal trading revenues of€ 13 billion, as well as nearly 13,000 employees in more than110 companies worldwide, Heraeus holds a leading position inits global markets.EnquiriesDr Andrew WilliamsonHead of Business DevelopmentHeraeus Medical GmbHandrew.williamson@heraeus.com- 2 -